; and (2) not later than 1 year after the date of enactment of this Act, submits a report on such study to the Secretary. (d) Review of opioid analgesic drugs In connection with the meeting described in subsection (a), the Anesthetic and Analgesic Drug Products Advisory Committee and the Drug Safety and Risk Management Advisory Committee of the Food and Drug Administration shall review the approved labeling and action package for approval (as described in subsection (l)(2) of section 505 of the Federal Food, Drug, and Cosmetic Act ( 21 U.S.C. 355 )), on all opioid analgesic drugs approved using enriched enrollment randomized withdrawal methodology under such section 505 as of the date of such meeting. The findings from such review shall be made publicly available on a website operated by the Secretary, acting through the Commissioner of Food and Drugs. (e) Definition of opioid analgesic drug In this section, the term opioid analgesic drug means a drug that has a labeled indication approved by the Food and Drug Administration to produce analgesia by acting upon the body’s opioid receptors. 117. Approval of new opioid analgesic drugs Section 505(c) of the Federal Food, Drug, and Cosmetic Act ( 21 U.S.C. 355(c) ) is amended by adding at the end the following: (6) Notwithstanding any other provision of this section, in making a determination to approve or deny an application submitted under subsection (b) for an opioid analgesic drug, the Secretary may consider whether such drug provides a substantial improvement, in terms of greater safety or greater effectiveness, or major contribution to patient care, compared to an approved opioid analgesic drug. For purposes of this paragraph, the term opioid analgesic drug means a drug that is approved under this section to produce analgesia by acting upon the body’s opioid receptors. . 118. Guidance on developing non-addictive medical products to treat pain or addiction Not later than 1 year after the date of enactment of this Act, the Secretary of Health and Human Services